ERBB2 and neoplasm: After 2 months of treatment, the tumor is evaluated as partial response with PFS of 12 months.<h4>Conclusions</h4>We presented a patient with HER2-positive GC who benefited from the pyrotinib-based treatment after two lines of trastuzumab-based therapies failed.